Journals / Erciyes Tıp Dergisi / 2013 / Cilt: 35 - Sayı: 1

Katı solid rifampisinin nano-parçacıklarının formülasyon ve karakterizasyonu

Formulation and characterization of solid lipid nanoparticles of rifampicin

Pages
1–5
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this regard, solid lipid nanoparticleshave emerged as a novel drug carrier system for the hydrophobic anti-tubercular drug, rifampicin.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, solid lipid nanoparticles of rifampicinwere prepared by the emulsion solvent diffusion method usingstearic acid to retard release and achieve the required releaseprofile for the treatment of tuberculosis.Materials and Methods: The polymer DL-lactide/glycolide copolymer (PLGA) and lipid were dissolved in the organic phaseseparately.
📊
Key Findings & Data:Theorganic solvents were removed using a rotary flash evaporator.The SLNs were recovered by centrifugation and lyophilized.Results: The twelve prepared formulations showed that thehighest encapsulation efficiency was 78.79±0.1%.
💡
Conclusion & Impact:In this regard, solid lipid nanoparticleshave emerged as a novel drug carrier system for the hydrophobic anti-tubercular drug, rifampicin.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, solid lipid nanoparticles of rifampicinwere prepared by the emulsion solvent diffusion method usingstearic acid to retard release and achieve the required releaseprofile for the treatment of tuberculosis.Materials and Methods: The polymer DL-lactide/glycolide copolymer (PLGA) and lipid were dissolved in the organic phaseseparately. Stearic acid and rifampicin were dissolved in a mixture of chloroform and methanol. The resulting organic solution was poured into polyvinyl alcohol and homogenized. Theorganic solvents were removed using a rotary flash evaporator.The SLNs were recovered by centrifugation and lyophilized.Results: The twelve prepared formulations showed that thehighest encapsulation efficiency was 78.79±0.1%. In vitrorelease studies were performed in which the particle stabilitywas found to be enhanced by poly vinyl alcohol (PVA), whichforms a barrier to the release of the incorporated drug. The stability study conducted for three months revealed that formulations stored at room temperature were prone to fungal growthwhereas formulations stored in the refrigerator were stable.Conclusion: The ultimate goal of controlled drug release is tomaximize therapeutic activity while minimizing the negativeside effects of the drug. In this regard, solid lipid nanoparticleshave emerged as a novel drug carrier system for the hydrophobic anti-tubercular drug, rifampicin.

Özet

Amaç: Bu çalışmada, salımı geciktirmek ve tüberküloz tedavisinde gerekli olan serbest bırakma profiline ulaşmak için, katılipid rifampisin nanopartikülleri stearik asit kullanarak, emülsiyon çözücü difüzyon yöntem ile hazırlandı. Gereç ve Yöntemler: Polimer DL-laktid/glikolid kopolimeri(PLGA) ve lipid ayrı ayrı organik faz içinde çözüldü. Stearik asit ve rifampisin, kloroform ve metanol karışımı içinde çözüldü. Elde edilen organik solüsyon poli vinil alkol içine döküldü ve homojenize edildi. Organik çözücüler döner flaş buharlaştırıcı ile uzaklaştırıldı. Oluşan SLNs santrifüjleme ile elde edildi veliyofilize edildi. Bulgular: Hazırlanan on iki formülasyon, %78,79±0,1’luk en yüksek kapsülleme etkinliğinin elde edildiğini gösterdi. in vitro salınım çalışmaları sırasında, inkorpore edilen ilacın serbest bırakılması için bir bariyer oluşturan PVA ile kullanılarakyapıldı. Üç ay boyunca yürütülen çalışmalar, soğutma altında saklanan formülasyonların stabil olduğunu ancak oda sıcaklığında saklanan formülasyonlarda mantar üreme eğilimli olduğunu ortaya koydu. Sonuç: Kontrollü ilaç salım için nihai hedef, ilacın olumsuzyan etkileri en aza indirirken terapötik etkinliğini maksimizeetmektir. Bu bağlamda, katı lipid nanopartiküller, hidrofobik Antitüberküloz ilaçlardan rifampisin için yeni ilaç taşıyıcı sistem olabilir.

🔖

Cite This Article

PENMATSA, S. D., SİVADASAN, D., MADAVAN, B., BATHİNİ, S. T. (2022). Katı solid rifampisinin nano-parçacıklarının formülasyon ve karakterizasyonu. Erciyes Tıp Dergisi, Cilt: 35 - Sayı: 1, 1–5. https://ajindex.com/articles/502407

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Eliana B. Souto, Rainer H. Müller, Lipid nanoparticles (SLN and NLC) for drug delivery, In: Domb AJ, Tabata Y, Ravi Kumar MNV, Farber S, Editors. Nanoparticles for Pharmaceutical Applications. Los Angeles, California: American Scientific Publishers; 2007.p.103-22
  2. Vyas SP Khar RK. Targeted and Controlled Drug Delivery: Novel Carrier Systems. 1st ed. New Delphi: CBS Publishers; 2002
  3. Tabatt K, Kneuer C, Sameti M, Olbrich C, Müller RH, Lehr CM, et al. Transfection with different colloidal systems: comparison of solid lipid nanopar- ticles and liposomes. J Control Release 2004; 97(2): 321-32. [CrossRef] 4. Mehnert W Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2-3): 165-96 [CrossRef] 5. Quenelle DC, Winchester GA, Staas JK, Barrow EL, Barrow WW. Tre- atment of tuberculosis using a combination of sustained-release rifam- pin-loaded microspheres and oral dosing with isoniazid. Antimicrob Agents Chemother 2001; 45(6): 1637-44. [CrossRef] 6. Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, prog- ress and challenges. J Antimicrob Chemother 2005; 55(4): 430-5. [CrossRef] 7. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intra- venous and intraduodenal administration. J Control Release 2005; 107(2): 215-28. [CrossRef] 8. Vijaya Raghavan C. Experimental Biopharmaceutics and Pharmacoki- netics. 1st ed. India: New Century. 2006
  4. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004; 95(3): 627-38. [CrossRef] 10. Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb) 2005; 85(5-6): 415-20. [CrossRef] 11. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl al- cohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002; 82(1): 105-14. [CrossRef]